0
Signin
countryflagUS

18889881171

AAPL 169.89 0.5147% MSFT 399.04 -2.4495% GOOG 157.95 -1.9553% GOOGL 156.0 -1.9669% AMZN 173.67 -1.6535% NVDA 826.32 3.7087% META 441.38 -10.5613% TSLA 170.18 4.9652% TSM 136.58 2.7149% LLY 724.87 -1.0011% V 275.16 0.0509% AVGO 1294.42 2.9917% JPM 193.37 0.1502% UNH 493.86 1.3462% NVO 125.79 -0.2933% WMT 60.21 0.5679% LVMUY 167.91 -2.1618% XOM 121.35 0.2478% LVMHF 837.0 -2.6461% MA 462.11 -0.0843%

Onconova Therapeutics Inc

Healthcare US ONTX

0.6414USD
-7.2886(91.91%)

Last update at 2024-04-24T13:30:00Z

Day Range

0.630.67
LowHigh

52 Week Range

0.551.49
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -18.96400M -16.16300M -25.15300M -21.49300M -20.53400M
Minority interest - - - 0.00000M -0.16300M
Net income -18.30100M -15.82800M -25.15700M -21.50300M -20.57300M
Selling general administrative 8.45M 9.43M 8.33M 8.35M 7.59M
Selling and marketing expenses - - - - -
Gross profit 0.23M 0.23M 0.23M 2.18M 1.23M
Reconciled depreciation 0.01M 0.01M 0.01M 0.01M 0.06M
Ebit -19.64100M -16.49600M -24.99300M -21.69900M -24.93400M
Ebitda -19.62700M -16.81700M -24.78500M -21.76200M -24.87900M
Depreciation and amortization 0.01M -0.32100M 0.21M -0.06300M 0.06M
Non operating income net other - - -0.16000M 0.21M 2.75M
Operating income -19.62700M -16.49600M -24.99300M -21.69900M -23.28200M
Other operating expenses 19.85M 16.72M 25.22M 23.88M 24.51M
Interest expense -0.01400M 0.34M 0.35M 0.28M 0.00000M
Tax provision - 0.00000M 0.00400M 0.01000M -0.12400M
Interest income - - - 0.06M 1.60M
Net interest income - - - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.66300M -0.33500M 0.00400M 0.01000M -0.12400M
Total revenue 0.23M 0.23M 0.23M 2.18M 1.23M
Total operating expenses 19.85M 16.72M 25.22M 23.88M 24.51M
Cost of revenue - - - - 0.00000M
Total other income expense net 0.66M 0.33M -0.16000M 0.21M 2.75M
Discontinued operations - - - - -
Net income from continuing ops -18.96400M -16.16300M -25.15700M -21.50300M -20.41000M
Net income applicable to common shares -18.96400M -16.16300M -25.15700M -21.50300M -20.57300M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 39.37M 55.48M 19.99M 23.67M 17.92M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.56M 0.33M 0.72M 0.65M 0.76M
Total liab 11.06M 9.36M 13.81M 12.10M 12.54M
Total stockholder equity 28.31M 46.12M 6.17M 11.57M 5.39M
Deferred long term liab - - - - -
Other current liab 3.96M 3.13M 4.96M 3.79M 0.01M
Common stock 0.21M 0.21M 1.86M 1.11M 0.06M
Capital stock 0.21M 0.21M 1.86M 1.11M 0.06M
Retained earnings -463.68300M -444.71900M -428.55600M -403.39900M -381.89600M
Other liab 3.02M 3.24M 3.79M 3.81M 4.10M
Good will - - - - -
Other assets 0.00100M 0.01000M 0.15M 0.15M 0.15M
Cash 38.76M 55.07M 19.02M 22.73M 16.97M
Cash and equivalents - - - - -
Total current liabilities 8.05M 6.12M 10.02M 8.29M 8.44M
Current deferred revenue 0.23M 0.23M 0.23M 0.23M 0.23M
Net debt -38.75700M -55.07000M -19.02500M -22.72600M -16.97000M
Short term debt - - - - 4.16M
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity 491.82M 490.64M 432.86M 413.88M 387.24M
Property plant equipment 0.02M 0.04M 0.05M 0.05M 0.00900M
Total current assets 39.35M 55.43M 19.78M 23.47M 17.77M
Long term investments - - - - -
Net tangible assets 28.31M 46.12M 6.17M 11.57M 5.39M
Short term investments - - - - -
Net receivables 0.03M 0.03M 0.04M 0.10M 0.04M
Long term debt - - - - -
Inventory - 0.03M 0.09M 0.03M 0.11M
Accounts payable 3.86M 2.76M 4.83M 4.27M 4.04M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.03300M -0.01400M 0.01M -0.01800M -0.01200M
Additional paid in capital - - - - -
Common stock total equity - - 1.86M 1.11M 0.06M
Preferred stock total equity - - - - -
Retained earnings total equity - - -428.55600M -403.39900M -381.89600M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.00100M 0.01000M 0.15M 0.15M 0.15M
Deferred long term asset charges - - - - -
Non current assets total 0.03M 0.05M 0.20M 0.20M 0.16M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments - 0.00000M -0.01500M -0.05500M 0.00000M
Change to liabilities 0.00000M -2.30200M 0.34M 0.23M -1.45400M
Total cashflows from investing activities - - -0.01500M -0.05500M -0.05500M
Net borrowings - - - - -
Total cash from financing activities 0.00000M 55.56M 19.36M 26.65M 35.66M
Change to operating activities - -1.30000M 1.09M -0.26900M 0.76M
Net income -18.96400M -16.16300M -25.15700M -21.50300M -20.41000M
Change in cash -16.31300M 36.05M -3.70100M 5.76M 12.95M
Begin period cash flow 55.07M 19.02M 22.73M 16.97M 4.02M
End period cash flow 38.76M 55.07M 19.02M 22.73M 16.97M
Total cash from operating activities -16.29400M -19.48700M -23.07500M -20.83100M -22.69600M
Issuance of capital stock 0.00000M 55.04M 9.06M 21.76M 35.07M
Depreciation 0.01M 0.01M 0.01M 0.01M 0.06M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - -9000.00000M -0.06100M 63000.00M -23999.21500M
Change to account receivables -0.00100M 9000.00M 0.06M -63000.00000M 24000.00M
Sale purchase of stock - - 19.36M 26.65M 35.66M
Other cashflows from financing activities - 0.52M 10.29M 4.89M 0.59M
Change to netincome - 0.26M 0.58M 0.98M -1.27400M
Capital expenditures 0.00000M 0.00000M 0.01M 0.06M 0.06M
Change receivables - - 0.06M -0.06300M 0.02M
Cash flows other operating - - -0.29800M -0.49600M 0.36M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - -3.73300M 5.76M 12.96M
Change in working capital 1.48M -3.59300M 1.49M -0.32700M -1.06700M
Stock based compensation 1.17M 0.58M 0.37M 1.05M 1.15M
Other non cash items - -0.32100M 0.21M -0.06300M -2.25800M
Free cash flow -16.29400M -19.48700M -23.09000M -20.88600M -22.69600M

Fundamentals

  • Previous Close 7.93
  • Market Cap15.21M
  • Volume39713
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-21.55400M
  • Revenue TTM0.23M
  • Revenue Per Share TTM0.01
  • Gross Profit TTM 0.23M
  • Diluted EPS TTM-0.96

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ONTX
Onconova Therapeutics Inc		 -7.2886 91.91% 0.64 - - 69.14 1.03 150.47 0.48
NVO
Novo Nordisk A/S		 -0.37 0.29% 125.79 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -3.3 2.60% 123.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -3.06 0.76% 397.70 30.40 24.75 10.68 6.25 9.52 20.36
CSLLY
CSL Ltd		 0.06 0.07% 90.16 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

View All

Profile

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Onconova Therapeutics Inc

12 Penns Trail, Newtown, PA, United States, 18940

Key Executives

Name Title Year Born
Dr. Steven M. Fruchtman M.D. CEO, Pres & Director 1951
Mr. Mark Patrick Guerin CPA CFO & COO 1969
Dr. Adar Makovski Silverstein Ph.D. Sr. Director & Head of Corp. Devel. NA
Dr. Mark Stephen Gelder M.D. Chief Medical Officer 1957

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).